The Patent Finder

Wellkey Holdings Limited

8 patents currently held · Updated Nov 19, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
7
Ending by 2030
Nov 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 4, 2027
    The maintenance fee for Composition for anti-aging or antioxidant composition containing plant stem cell line derived from cambium or Panax ginseng including wild ginseng and ginseng as active components (US 9,095,532) comes due Feb 4, 2027. Unpaid by Aug 4, 2027, it lapses early.
  • 1 fee due Sep 22, 2027
    The maintenance fee for Composition for preventing or treating liver diseases, containing plant stem cell lines derived from the cambium of Panax ginseng including mountain ginseng or ginseng as active ingredient (US 9,289,457) comes due Sep 22, 2027. Unpaid by Mar 22, 2028, it lapses early.
  • 1 fee due Oct 19, 2027
    The maintenance fee for Composition for cancer prevention or treatment containing as active ingredient plant stem cell line dervied from cambium of Panax ginseng including wild ginseng or ginseng (US 9,314,492) comes due Oct 19, 2027. Unpaid by Apr 19, 2028, it lapses early.
  • 1 fee due Nov 12, 2027
    The maintenance fee for Method for preparing extract of genus Panax including wild ginseng or ginseng, or cambial meristematic cells derived from genus panax or extract thereof containing rare ginsenosides in high quantity (US 10,646,528) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 21, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,585,923Antioxidant, anti-inflammatory or anti-aging composition containing taxus cambium- or procambium-derived cell line as active ingredient
In force
 · USPTO record
In forceUSPTO record
US 8,247,230Plant stem cell line derived from cambium of herbaceous plant with storage root and method for isolating the same
In force
 · USPTO record
In forceUSPTO record
US 9,095,532Composition for anti-aging or antioxidant composition containing plant stem cell line derived from cambium or Panax ginseng including wild ginseng and ginseng as active components
In force
 · USPTO record
In forceUSPTO record
US 8,617,621Composition for enhancing immunity containing plant stem cell line derived from cambium of Panax ginseng including wild ginseng or ginseng as an active ingredient
In force
 · USPTO record
In forceUSPTO record
US 9,314,492Composition for cancer prevention or treatment containing as active ingredient plant stem cell line dervied from cambium of Panax ginseng including wild ginseng or ginseng
In force
 · USPTO record
In forceUSPTO record
US 9,415,081Composition for preventing or treating AIDS containing plant stem cell line derived from cambium of Panax ginseng including wild ginseng or ginseng as active ingredient
In force
 · USPTO record
In forceUSPTO record
US 9,289,457Composition for preventing or treating liver diseases, containing plant stem cell lines derived from the cambium of Panax ginseng including mountain ginseng or ginseng as active ingredient
In force
 · USPTO record
In forceUSPTO record
US 10,646,528Method for preparing extract of genus Panax including wild ginseng or ginseng, or cambial meristematic cells derived from genus panax or extract thereof containing rare ginsenosides in high quantity
In force
 · USPTO record
In forceUSPTO record
Also on record, not counted in the 8: 2 lapsed for an unpaid fee · 3 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

Every application published under this name has become a patent.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited